According to The Insight Partners' research, the Europe Pharmaceuticals Market was valued at US$ 317.3 Billion in 2024 and is expected to reach US$ 446.9 Billion by 2031, registering a CAGR of 5.0% from 2025 to 2031.
Expanding global access to medicines and growing emerging markets and harnessing innovation, AI, and market expansion are among the critical factors attributed to the Europe Pharmaceuticals Market expansion.
As the pharmaceutical industry evolves, global medicine use has significantly increased due to improved access to medications. Medicine use, measured in defined daily doses, has increased by 36% over the past decade due to greater availability and adoption of treatments. However, growth is expected to slow through 2027, with total medicine use reaching US$3.4 trillion doses-an 8% increase from 2022 levels. The highest volume growth is anticipated in Latin America, Asia, and Africa, largely due to a combination of population expansion and improved healthcare accessibility. At the same time, North America and Europe will see very low growth. Pharmaceutical spending also reflects these trends. The global medicine market is expected to grow at a compound annual growth rate (CAGR) of 3-6% through 2027, reaching $ 1.9 trillion. The growth trajectory varies by region-developed economies will maintain steady growth rates as new products offset losses from patent expiries. At the same time, Latin America, Eastern Europe, and parts of Asia will see robust expansion due to volume increases and higher adoption of innovative medicines. The role of Italy as a key player in the pharmaceutical industry further exemplifies the shift toward international markets. With a pharmaceutical production value of 32 billion in 2018, Italy led the EU in supply chain quality. Between 2008 and 2018, pharmaceutical exports from Italy surged by 117%-double the 58% average growth of other major EU countries. The momentum continued in 2019, with exports rising by 29%. Foreign investment in Italy's life sciences sector is also thriving, as 60% of pharma companies based in the country are foreign-owned. The nation's pharmaceutical workforce is highly skilled, with 66,500 employees (+8.6% over five years), 90% of whom hold a secondary school certification or university degree. This educated and adaptable workforce is a major attraction for global companies investing in Italy.
Global medicine use and pharmaceutical spending are rising steadily, driven by improved access and expanding populations in emerging regions. While mature markets face slower growth due to patent expirations and biosimilar competition, innovation in specialty and biotech drugs sustains demand. International hubs with skilled workforces, like Italy, highlight the shift toward globalized production and investment. Policy changes, such as those affecting pricing and cost-sharing, add complexity but also opportunity for adaptation. Overall, the industry's growth will be shaped by regional dynamics, technological advances, and collaborative efforts across the healthcare ecosystem.
On the contrary, regulatory pressures and market shifts hampers the growth of Europe Pharmaceuticals Market.
Europe Pharmaceuticals Market Segmentation Analysis:
- By Molecule Type, the Europe Pharmaceuticals Market is segmented into Small Molecule and Biological and Biosimilar Products. The Small Molecule segment is projected to expand at 2.2% CAGR during 2025 - 2031.
- By Indication, the Europe Pharmaceuticals Market is segmented into Metabolic Diseases, Cancer, Immunology, Respiratory Disorder, Cardiovascular Disorder, Neurology Disorder, Rare Disease, and Others. the Cancer segment is projected to expand at 5.4% CAGR during 2025 - 2031.
- By Product, the Europe Pharmaceuticals Market is segmented into Branded and Generic. The Branded segment is projected to expand at 5.8% CAGR during 2025 - 2031.
- By Type, the Europe Pharmaceuticals Market is segmented into Prescription and OTC Drugs. The Prescription segment is projected to expand at 5.3% CAGR during 2025 - 2031.
- By Distribution Channel, the Europe Pharmaceuticals Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment is projected to expand at 5.6% CAGR during 2025 - 2031.
By country, the Europe Pharmaceuticals Market is categorized into the United Kingdom, Germany, France, Italy, Spain, and the Rest of Europe. The Rest of Europe is projected to expand at 2.8% CAGR during 2025 - 2031.
Key players operating in the Pharmaceuticals Market are GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Viatris Inc, Sanofi SA, Bristol-Myers Squibb Co, Johnson & Johnson, AstraZeneca Plc, AbbVie Inc, Eli Lilly and Co, Hikma Pharmaceuticals Plc, UCB SA, and ESTEVE, among others.
- In February 2025, Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for an expanded indication of DARZALEX (daratumumab) subcutaneous (SC) formulation. This recommendation is for its use in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) to treat adults with newly diagnosed multiple myeloma (NDMM).
- In November 2024, Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for HYMPAVZI (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A (congenital factor VIII [FVIII] deficiency, FVIII <1%) without FVIII inhibitors or severe hemophilia B (congenital factor IX [FIX] deficiency, FIX <1%) without FIX inhibitors.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com